FDA Brief

Warning letters Drugs

FDA warning letter to

Dexterity Health, LLC DBA Zazzee Naturals

High riskIssued Oct 30, 2023Posted Nov 7, 2023Center for Drug Evaluation and Research | CDER

Zazzee Naturals sells Liquid MSM eye drops online as an unapproved new drug, FDA says in warning letter.

What happened

FDA reviewed the company's Amazon storefront listings in September 2023 and found Liquid MSM Drops offered for sale in the United States. The listing claims the drops heal damage to the eyes, soften eye membranes, reduce joint pain and lower inflammation, which FDA says makes the product a drug. No FDA-approved application is in effect for it, so FDA calls it an unapproved new drug. No inspection was involved.

What FDA found

  1. The product is a drug because the listing claims it treats eye damage and affects how the body works.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  2. The product is a "new drug" because it is not generally recognized as safe and effective for the uses claimed.

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. The company sells the product without an FDA-approved drug application in effect.

    Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  4. Shipping the product across state lines violates the law because it is an unapproved drug.

    Section 301(d) of the FD&C Act, 21 U.S.C. 331(d)

What FDA wants

FDA asks the company to write to CDER's Office of Unapproved Drugs and Labeling Compliance within fifteen working days describing the steps taken to fix the violations and prevent them from happening again, with supporting documents. If the company believes the product is not in violation, it should send its reasoning and evidence; if corrections cannot be finished in that time, it should explain why and give a completion date.

Who should pay attention

  • online sellers of eye drops and supplement-style products
  • brands making drug-like claims for MSM or eye-health products
  • marketplaces and retailers listing unapproved drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk